GREENWICH LIFESCIENC

GLSI

Delayed - 01/26 04:00:00 pm
36.54USD	+1.05%

Turn to zoom

Prev.	36.1600
Open	36.2500
High	41.7700
Low	35.6805
Volume	470 242

8h ago	Greenwich LifeSciences : Aegis Capital Initiates Coverage on Greenwich...
5d ago	Greenwich LifeSciences : to Present at B. Riley Securities and BIO CEO &...
01/08	Greenwich LifeSciences : to Participate in Multiple Virtual Investor...
01/05	Greenwich LifeSciences : rsquo; LD Micro Presentation Replay Now Available

	Short Term	Mid-Term	Long Term
Trend	Bearish	Neutral	Neutral
Resistance	42,7	72,2	56,0
Spread/Res.	-14%	-49%	-35%
Spread/Supp.	6,1%	952%	952%
Support	34,5	3,48	3,48

Sales 2019	- - -
Net income 2019	-3,43 M - -
Net Debt 2019	0,63 M - -
P/E ratio 2019	-
Yield 2019	-

Capitalization	464 M 464 M -
EV / Sales 2018	-
EV / Sales 2019	-
Nbr of Employees	-
Free-Float	20,0%

Greenwich LifeSciences, Inc. is a clinical stage biopharmaceutical company. The Company is engaged in developing GP2, an immunotherapy designed to prevent the recurrence of breast cancer following surgery. GP2 is a nine amino acid transmembrane peptide of the human epidermal growth factor receptor...

>> Read more

Sector :

Biopharmaceuticals

Calendar :

2021-02-16 Presentation